Search PubMed⌕ Search

Biomedical subjects

L Wood

Publications and source records attributed to L Wood.

257 records · Page 15Linked to original sources

Research and development in haematology. A report on international congresses and visit to academic centres in Europe.

Haematology is one of the most rapidly expanding disciplines in medicine and nursing. As occurs in other highly specialised areas, optimum care is now largely of a multidisciplinary nature. In this context there are literally unlimited opportunities for the involvement of professional nurses and, as I have attempted to illustrate in this report, integration in all aspects of research and development and active participation in presentation of research data and discussion at international meetings is one direction in which fulfillment of academic aspirations can be achieved. It is my viewpoint, based on more than a decade of direct involvement in all the activities of our department in Cape Town that these are entirely attainable goals. There is currently, in our country, a concerted move afoot to develop an improved career structure for the professional nurse along the lines of the American clinical nurse specialist. Much of this experience overseas would strongly support that commitment. It was my privilege to enjoy the confidence of the department, university and medical school sufficient for me to present research data at international meetings and to be a welcome visitor at some of the world's premier academic and research institutions. That this was possible reflects the uncompromising commitment in Haematology to the position of the professional nurse as an integral and equal part of the multidisciplinary health care team.

Academic Medical Centers↗

Innovative antineoplastic agents.

Cancer treatment options are changing as a result of extensive research efforts. New drugs and drug combinations proceed through specific phases of clinical research leading to possible Food and Drug Administration review and approval. Phase I, II, III, and IV clinical trials have detailed enrollment criteria and treatment plans designed to determine research objectives. These objectives can include reduction of toxicity, increased efficacy, and improved quality of life. Liposomal drug formulations, monoclonal antibody therapies, and cytoprotective agents are some of the new treatment approaches that have shown promise in clinical trials. This article reviews the clinical trial process, several innovative therapies, and the nursing responsibilities associated with caring for the patient with cancer.

Antibodies, Monoclonal↗

Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships.

Superoxide dismutases catalyse the dismutation of highly reactive superoxide ions to produce hydrogen peroxide and several lines of evidence suggest that these enzymes play important roles in the development and response to treatment of human cancers. For example, Mn-containing superoxide dismutase is frequently overexpressed in various cancer types and can contribute to resistance to apoptosis. 2-Methoxyoestradiol is a naturally occurring metabolic product of 17beta-oestradiol that inhibits tubulin polymerization and possesses growth inhibitory and cytotoxic activity in vitro and in vivo. More recently 2-methoxyoestradiol has also been shown to inhibit superoxide dismutase (SOD) in a tetrazolium salt based enzyme assay, suggesting that oestrogen derivatives might be useful starting points for the development of effective, non-toxic enzyme inhibitors. Here we have tested the SOD inhibiting activity of a range of oestrogen derivatives to determine structural features important for enzyme inhibition.

2-Methoxyestradiol↗

Computer crisis.

Explore the source record for details and available documents.

Computers↗